Log in to search using one of your social media accounts:


Leukemic mesenchymal stromal cell COX2-PG signaling regulates donor anti-leukemia immunity

Hematopoietic stem cell transplantation (HSCT) is considered the gold standard for treatment of hematologic malignancies, including Fanconi anemia (FA), a cancer-prone disease with extremely high incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, eradication of residual leukemia stem cells (LSCs), which often contributes to relapse, remains the challenge for HSCT. Here we investigate the interaction between leukemic mesenchymal niche and donor hematopoietic stem progenitor cells (HSPCs) by modeling FA HSCT.
Source: Experimental Hematology - Category: Hematology Authors: Source Type: research

Related Links:

More News: Acute Leukemia | Acute Myeloid Leukemia | Anemia | Cancer | Cancer & Oncology | Faconi Anemia | Hematology | Leukemia | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Transplants